Introduction: Mast cells are known for their involvement in allergic reactions but also in inflammatory reactions via secretion of numerous pro-inflammatory chemokines, cytokines, and enzymes. Drug development has focused on antiproliferative therapy for systemic mastocytosis and not on inhibitors of mast cell activation. The only drug available as a “mast cell blocker” is disodium cromoglycate (cromolyn), but it is poorly absorbed after oral administration, is a weak inhibitor of histamine release from human mast cells, and it develops rapid anaphylaxis. Instead, certain natural flavonoids, especially luteolin, can inhibit mast cell activation. Methods: Here, we compared pretreatment (0–120 min) with equimolar concentration (effective dose for 50% inhibition = 100 mm for inhibition of histamine release by cromolyn) of cromolyn and luteolin on release of mediators from the cultured human LADR mast cell line stimulated either by immunoglobulin E (IgE) and anti-IgE or with IL-33. Results: We show that luteolin is significantly more potent than cromolyn inhibiting release of histamine, tryptase, metalloproteinase-9, and vascular endothelial growth factor. Moreover, while luteolin also significantly inhibited release of IL-1β, IL-6, and IL-8 (CXCL8) and TNF, cromolyn had no effect. Conclusion: These findings support the use of luteolin, especially in liposomal form to increase oral absorption, may be a useful alternative to cromolyn.

1.
Theoharides
TC
,
Valent
P
,
Akin
C
.
Mast cells, mastocytosis, and related disorders
.
N Engl J Med
.
2015
;
373
(
2
):
163
72
. doi: .
2.
Levi-Schaffer
F
,
Gibbs
BF
,
Hallgren
J
,
Pucillo
C
,
Redegeld
F
,
Siebenhaar
F
, et al
.
Selected recent advances in understanding the role of human mast cells in health and disease
.
J Allergy Clin Immunol
.
2022
;
149
(
6
):
1833
44
. doi: .
3.
Valent
P
,
Hartmann
K
,
Bonadonna
P
,
Niedoszytko
M
,
Triggiani
M
,
Arock
M
, et al
.
Mast cell activation syndromes: collegium internationale allergologicum update 2022
.
Int Arch Allergy Immunol
.
2022
;
183
(
7
):
693
705
. doi: .
4.
Theoharides
TC
,
Leeman
SE
.
Effect of IL-33 on de novo synthesized mediators from human mast cells
.
J Allergy Clin Immunol
.
2019
;
143
(
1
):
451
. doi: .
5.
Theoharides
TC
,
Perlman
AI
,
Twahir
A
,
Kempuraj
D
.
Mast cell activation: beyond histamine and tryptase
.
Expert Rev Clin Immunol
.
2023
;
19
(
6
):
639
54
. doi: .
6.
Valent
P
,
Hartmann
K
,
Bonadonna
P
,
Niedoszytko
M
,
Triggiani
M
,
Arock
M
, et al
.
Mast cell activation syndromes: collegium internationale allergologicum update 2022
.
Int Arch Allergy Immunol
.
2022
;
183
(
7
):
693
705
. doi: .
7.
Mukai
K
,
Tsai
M
,
Saito
H
,
Galli
SJ
.
Mast cells as sources of cytokines, chemokines, and growth factors
.
Immunol Rev
.
2018
;
282
(
1
):
121
50
. doi: .
8.
Kolkhir
P
,
Elieh-Ali-Komi
D
,
Metz
M
,
Siebenhaar
F
,
Maurer
M
.
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
.
Nat Rev Immunol
.
2022
;
22
(
5
):
294
308
. doi: .
9.
Akin
C
,
Arock
M
,
Valent
P
.
Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet
.
J Allergy Clin Immunol
.
2022
;
149
(
6
):
1912
8
. doi: .
10.
Horan
RF
,
Sheffer
AL
,
Austen
KF
.
Cromolyn sodium in the management of systemic mastocytosis
.
J Allergy Clin Immunol
.
1990
;
85
(
5
):
852
5
. doi: .
11.
Okayama
Y
,
Church
MK
.
Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells
.
Int Arch Allergy Immunol
.
1992
;
97
(
3
):
216
25
. doi: .
12.
Kimata
M
,
Shichijo
M
,
Miura
T
,
Serizawa
I
,
Inagaki
N
,
Nagai
H
.
Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells
.
Clin Exp Allergy
.
2000
;
30
(
4
):
501
8
. doi: .
13.
Weng
Z
,
Patel
AB
,
Panagiotidou
S
,
Theoharides
TC
.
The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells
.
J Allergy Clin Immunol
.
2015
;
135
(
4
):
1044
52.e5
. doi: .
14.
Kirshenbaum
AS
,
Yin
Y
,
Sundstrom
JB
,
Bandara
G
,
Metcalfe
DD
.
Description and characterization of a novel human mast cell line for scientific study
.
Int J Mol Sci
.
2019
;
20
(
22
):
5520
. doi: .
15.
Church
MK
,
Gradidge
CF
.
Potentiation of histamine release by sodium cromoglycate
.
Life Sci
.
1978
;
23
(
19
):
1899
903
. doi: .
16.
Church
MK
,
Young
KD
.
The characteristics of inhibition of histamine release from human lung fragments by sodium cromoglycate, salbutamol and chlorpromazine
.
Br J Pharmacol
.
1983
;
78
(
4
):
671
9
. doi: .
17.
Theoharides
TC
,
Sieghart
W
,
Greengard
P
,
Douglas
WW
.
Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein
.
Science
.
1980
;
207
(
4426
):
80
2
. doi: .
18.
Church
MK
,
Hiroi
J
.
Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol
.
Br J Pharmacol
.
1987
;
90
(
2
):
421
9
. doi: .
19.
Weng
Z
,
Zhang
B
,
Asadi
S
,
Sismanopoulos
N
,
Butcher
A
,
Fu
X
, et al
.
Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans
.
PLoS One
.
2012
;
7
(
3
):
e33805
. doi: .
20.
Yanni
JM
,
Miller
ST
,
Gamache
DA
,
Spellman
JM
,
Xu
S
,
Sharif
NA
.
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells
.
Ann Allergy Asthma Immunol
.
1997
;
79
(
6
):
541
5
. doi: .
21.
Lieberman
JA
,
Zhang
J
,
Whitworth
J
,
Cavender
C
.
A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis
.
Ann Allergy Asthma Immunol
.
2018
;
120
(
5
):
527
31
. doi: .
22.
Vieira Dos Santos
R
,
Magerl
M
,
Martus
P
,
Zuberbier
T
,
Church
MK
,
Escribano
L
, et al
.
Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus
.
Br J Dermatol
.
2010
;
162
(
3
):
674
6
. doi: .
23.
Theoharides
TC
,
Stewart
JM
,
Tsilioni
I
.
Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion
.
Int J Immunopathol Pharmacol
.
2017
;
30
(
2
):
146
51
. doi: .
24.
Oka
T
,
Kalesnikoff
J
,
Starkl
P
,
Tsai
M
,
Galli
SJ
.
Evidence questioning cromolyn's effectiveness and selectivity as a “mast cell stabilizer” in mice
.
Lab Invest
.
2012
;
92
(
10
):
1472
82
. doi: .
25.
Baolin
L
,
Weiwei
W
,
Ning
T
.
Topical application of luteolin inhibits scratching behavior associated with allergic cutaneous reaction in mice
.
Planta Med
.
2005
;
71
(
5
):
424
8
. doi: .
26.
Kandere-Grzybowska
K
,
Letourneau
R
,
Kempuraj
D
,
Donelan
J
,
Poplawski
S
,
Boucher
W
, et al
.
IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells
.
J Immunol
.
2003
;
171
(
9
):
4830
6
. doi: .
27.
Tobio
A
,
Bandara
G
,
Morris
DA
,
Kim
DK
,
O’Connell
MP
,
Komarow
HD
, et al
.
Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
.
Haematologica
.
2020
;
105
(
1
):
124
35
. doi: .
28.
Theoharides
TC
,
Boucher
W
,
Spear
K
.
Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients
.
Int Arch Allergy Immunol
.
2002
;
128
(
4
):
344
50
. doi: .
29.
Brockow
K
,
Akin
C
,
Huber
M
,
Metcalfe
DD
.
IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis
.
Clin Immunol
.
2005
;
115
(
2
):
216
23
. doi: .
30.
Mayado
A
,
Teodosio
C
,
Garcia-Montero
AC
,
Matito
A
,
Rodriguez-Caballero
A
,
Morgado
JM
, et al
.
Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression
.
Leukemia
.
2016
;
30
(
1
):
124
30
. doi: .
31.
Lee
EY
,
Jakubovic
BD
.
Interleukin-6 and cytokine release syndrome: a new understanding in drug hypersensitivity reactions
.
Ann Allergy Asthma Immunol
.
2023
;
130
(
2
):
178
84
. doi: .
32.
Herold
T
,
Jurinovic
V
,
Arnreich
C
,
Lipworth
BJ
,
Hellmuth
JC
,
von Bergwelt-Baildon
M
, et al
.
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
.
J Allergy Clin Immunol
.
2020
;
146
(
1
):
128
36.e4
. doi: .
33.
Copaescu
A
,
Smibert
O
,
Gibson
A
,
Phillips
EJ
,
Trubiano
JA
.
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection
.
J Allergy Clin Immunol
.
2020
;
146
(
3
):
518
34.e1
. doi: .
34.
Saluja
R
,
Khan
M
,
Church
MK
,
Maurer
M
.
The role of IL-33 and mast cells in allergy and inflammation
.
Clin Transl Allergy
.
2015
;
5
:
33
. doi: .
35.
Taracanova
A
,
Tsilioni
I
,
Conti
P
,
Norwitz
ER
,
Leeman
SE
,
Theoharides
TC
.
Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin
.
Proc Natl Acad Sci U S A
.
2018
;
115
(
40
):
E9381
E90
.
36.
Taracanova
A
,
Alevizos
M
,
Karagkouni
A
,
Weng
Z
,
Norwitz
E
,
Conti
P
, et al
.
SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors
.
Proc Natl Acad Sci U S A
.
2017
;
114
(
20
):
E4002
9
. doi: .
37.
Theoharides
TC
,
Zhang
B
,
Kempuraj
D
,
Tagen
M
,
Vasiadi
M
,
Angelidou
A
, et al
.
IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin
.
Proc Natl Acad Sci U S A
.
2010
;
107
(
9
):
4448
53
. doi: .
38.
Marcella
S
,
Petraroli
A
,
Braile
M
,
Parente
R
,
Ferrara
AL
,
Galdiero
MR
, et al
.
Vascular endothelial growth factors and angiopoietins as new players in mastocytosis
.
Clin Exp Med
.
2021
;
21
(
3
):
415
27
. doi: .
39.
Mantovani
A
,
Garlanda
C
.
Humoral innate immunity and acute-phase proteins. Reply
.
N Engl J Med
.
2023
;
388
(
18
):
1725
6
. doi: .
40.
Tsilioni
I
,
Theoharides
TC
.
Recombinant SARS-CoV-2 spike protein stimulates secretion of chymase, tryptase, and IL-1β from human mast cells, augmented by IL-33
.
Int J Mol Sci
.
2023
;
24
(
11
):
9487
. doi: .
41.
Motta Junior
JDS
,
Miggiolaro
A
,
Nagashima
S
,
de Paula
CBV
,
Baena
CP
,
Scharfstein
J
, et al
.
Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis
.
Front Immunol
.
2020
;
11
:
574862
. doi: .
42.
Wu
ML
,
Liu
FL
,
Sun
J
,
Li
X
,
He
XY
,
Zheng
HY
, et al
.
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury
.
Signal Transduct Target Ther
.
2021
;
6
(
1
):
428
. doi: .
43.
Gebremeskel
S
,
Schanin
J
,
Coyle
KM
,
Butuci
M
,
Luu
T
,
Brock
EC
, et al
.
Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-siglec-8 antibody
.
Front Immunol
.
2021
;
12
:
650331
. doi: .
44.
Theoharides
TC
.
Potential association of mast cells with coronavirus disease 2019
.
Ann Allergy Asthma Immunol
.
2021
;
126
(
3
):
217
8
. doi: .
45.
Afrin
LB
,
Weinstock
LB
,
Molderings
GJ
.
Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
.
Int J Infect Dis
.
2020
;
100
:
327
32
. doi: .
46.
Theoharides
TC
,
Kempuraj
D
.
Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID
.
Cells
.
2023
;
12
(
5
) Epub 20230222. doi: .
47.
Theoharides
TC
.
COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
.
Biofactors
.
2020
;
46
(
3
):
306
8
. doi: .
48.
Wang
W
,
Yang
C
,
Xia
J
,
Li
N
,
Xiong
W
.
Luteolin is a potential inhibitor of COVID-19: an in silico analysis
.
Medicine
.
2023
;
102
(
38
):
e35029
. doi: .
49.
Theoharides
TC
,
Cholevas
C
,
Polyzoidis
K
,
Politis
A
.
Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue
.
Biofactors
.
2021
;
47
(
2
):
232
41
. doi: .
50.
Theoharides
TC
,
Kempuraj
D
.
Potential role of moesin in regulating mast cell secretion
.
Int J Mol Sci
.
2023
;
24
(
15
):
12081
. doi: .
51.
Puzzovio
PG
,
Brüggemann
TR
,
Pahima
H
,
Mankuta
D
,
Levy
BD
,
Levi-Schaffer
F
.
Cromolyn Sodium differentially regulates human mast cell and mouse leukocyte responses to control allergic inflammation
.
Pharmacol Res
.
2022
;
178
:
106172
. doi: .
52.
Che
DN
,
Shin
JY
,
Kang
HJ
,
Cho
BO
,
Kim
YS
,
Jang
SI
.
Luteolin suppresses IL-31 production in IL-33-stimulated mast cells through MAPK and NF-κB signaling pathways
.
Int Immunopharmacol
.
2020
;
83
:
106403
. doi: .
53.
Nagata
K
,
Araumi
S
,
Ando
D
,
Ito
N
,
Ando
M
,
Ikeda
Y
, et al
.
Kaempferol suppresses the activation of mast cells by modulating the expression of FcεRI and SHIP1
.
Int J Mol Sci
.
2023
;
24
(
6
):
5997
. doi: .
54.
Patel
AB
,
Theoharides
TC
.
Methoxyluteolin inhibits neuropeptide-stimulated proinflammatory mediator release via mTOR activation from human mast cells
.
J Pharmacol Exp Ther
.
2017
;
361
(
3
):
462
71
. doi: .
55.
Hao
Y
,
Che
D
,
Yu
Y
,
Liu
L
,
Mi
S
,
Zhang
Y
, et al
.
Luteolin inhibits FcεRΙ- and MRGPRX2-mediated mast cell activation by regulating calcium signaling pathways
.
Phytother Res
.
2022
;
36
(
5
):
2197
206
. doi: .
56.
Seelinger
G
,
Merfort
I
,
Schempp
CM
.
Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin
.
Planta Med
.
2008
;
74
(
14
):
1667
77
. doi: .
57.
Aziz
N
,
Kim
MY
,
Cho
JY
.
Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies
.
J Ethnopharmacol
.
2018
;
225
:
342
58
. doi: .
58.
Hussain
MS
,
Gupta
G
,
Goyal
A
,
Thapa
R
,
Almalki
WH
,
Kazmi
I
, et al
.
From nature to therapy: luteolin’s potential as an immune system modulator in inflammatory disorders
.
J Biochem Mol Toxicol
.
2023
;
37
(
11
):
e23482
. doi: .
59.
Kempuraj
D
,
Thangavel
R
,
Kempuraj
DD
,
Ahmed
ME
,
Selvakumar
GP
,
Raikwar
SP
, et al
.
Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma
.
Biofactors
.
2021
;
47
(
2
):
190
7
. doi: .
60.
Yao
ZH
,
Yao
XL
,
Zhang
Y
,
Zhang
SF
,
Hu
JC
.
Luteolin could improve cognitive dysfunction by inhibiting neuroinflammation
.
Neurochem Res
.
2018
;
43
(
4
):
806
20
. doi: .
61.
Theoharides
TC
,
Conti
P
,
Economu
M
.
Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin
.
J Clin Psychopharmacol
.
2014
;
34
(
2
):
187
9
. doi: .
62.
Tsilioni
I
,
Taliou
A
,
Francis
K
,
Theoharides
TC
.
Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6
.
Transl Psychiatry
.
2015
;
5
(
9
):
e647
. doi: .
63.
Theoharides
TC
,
Twahir
A
,
Kempuraj
D
.
Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation
.
Ann Allergy Asthma Immunol
.
2023
:
S1081
1206(23)01397-2
. doi: .
You do not currently have access to this content.